MIT’s Non-Invasive Raman-Based CGM Achieves Accuracy Comparable to Commercial Devices, Signaling Next-Generation Glucose Monitoring Potential

August 9, 2026

Morld USA

Overview

MIT researchers have developed a novel Raman-based non-invasive continuous glucose monitoring (CGM) device that reads glucose through the skin without needles. Initial tests demonstrate accuracy comparable to existing commercial invasive CGMs, potentially revolutionizing glucose monitoring. Complementing this, Abbott’s Lingo emerges as a new over-the-counter (OTC) option for non-insulin users seeking real-time glucose insights.

In Depth

Key Findings

A team of researchers at the Massachusetts Institute of Technology (MIT) has developed a groundbreaking non-invasive continuous glucose monitoring (CGM) device based on Raman spectroscopy, which eliminates the need for skin-piercing needles. This innovative device has reportedly achieved glucose measurement accuracy comparable to currently available invasive commercial CGM systems in initial performance evaluations.

Technical/Clinical Details

The developed Raman-based device operates by directing laser light onto the skin and estimating glucose concentration from the vibrational information of biomolecules. This method bypasses the need for blood draws or subcutaneous sensor insertion, significantly reducing patient burden. While current CGMs primarily measure glucose concentrations in interstitial fluid, this non-invasive technology holds the potential to reflect blood glucose more directly, and its comparable accuracy to traditional systems marks a significant advance in medical technology. Additionally, Abbott’s ‘Lingo’ has been introduced as a new over-the-counter (OTC) option for general consumers who do not use insulin but wish to understand their real-time glucose profiles, fostering broader adoption of CGM technology.

Background & Context

For individuals with diabetes, continuous glucose monitoring is crucial for disease management, but existing CGMs require sensor insertion into the body, which can entail infection risks and discomfort. The development of non-invasive CGMs has been a long-standing challenge. If MIT’s technology gains widespread clinical application, it could dramatically improve the quality of life for diabetes patients and accelerate CGM adoption among pre-diabetics and health-conscious individuals, thereby significantly contributing to preventive medicine. The emergence of OTC products like Abbott’s Lingo further propels this trend.

Strategic Significance & Outlook

MIT’s non-invasive Raman-based CGM device requires further large-scale clinical trials to validate its efficacy and safety. If successful, it could revolutionize the medical device market and establish a new standard for diabetes management. Needle-free monitoring would particularly benefit pediatric patients and those with needle phobia, removing psychological and physical barriers to CGM adoption. Furthermore, integration with AI could enable personalized lifestyle advice based on measurement data, bringing a future of more integrated healthcare solutions into view.

Source: https://morld.com.tw/en/blog/continuous-glucose-monitors-the-hype-and-the-caveats

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.